{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:08:20Z","timestamp":1793880500041,"version":"4.7.0"},"reference-count":39,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine if the degree of baseline fibromyalgia (FM) symptoms in patients with rheumatoid arthritis (RA), as indicated by the Fibromyalgia Survey Questionnaire (FSQ) score, predicts RA disease activity after initiation or change of a disease-modifying antirheumatic drug (DMARD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>One hundred ninety-two participants with active RA were followed for 12 weeks after initiation or change of DMARD therapy. Participants completed the FSQ at the initial visit. The Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) was measured at baseline and follow-up to assess RA disease activity. We evaluated the association between baseline FSQ score and follow-up DAS28-CRP. As a secondary analysis, we examined the relationship between the 2 components of the FSQ, the Widespread Pain Index (WPI) and Symptom Severity Scale (SSS), with follow-up DAS28-CRP. Multiple linear regression analyses were performed, adjusting for clinical and demographic variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In multiple linear regression models, FSQ score was independently associated with elevated DAS28-CRP scores 12 weeks after DMARD initiation (B = 0.04,<jats:italic>P<\/jats:italic>= 0.01). In secondary analyses, the WPI was significantly associated with increased follow-up DAS28-CRP scores (B = 0.08,<jats:italic>P<\/jats:italic>= 0.001), whereas the SSS was not (B = \u22120.03,<jats:italic>P<\/jats:italic>= 0.43).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Higher levels of FM symptoms weakly predicted worse disease activity after treatment. The primary factor that informed the FSQ\u2019s prediction of disease activity was the spatial extent of pain, as measured by the WPI.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.220507","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T13:28:31Z","timestamp":1671110911000},"page":"684-689","source":"Crossref","is-referenced-by-count":5,"title":["Predicting Disease Activity in Rheumatoid Arthritis With the Fibromyalgia Survey Questionnaire: Does the Severity of Fibromyalgia Symptoms Matter?"],"prefix":"10.3899","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0657-1328","authenticated-orcid":false,"given":"Alexander M.","family":"Gorzewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3718-3886","authenticated-orcid":false,"given":"Andrew C.","family":"Heisler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9515-1711","authenticated-orcid":false,"given":"Tuhina","family":"Neogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8655-1484","authenticated-orcid":false,"given":"Lutfiyya N.","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8881-9664","authenticated-orcid":false,"given":"Jing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-3956","authenticated-orcid":false,"given":"Dorothy","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4752-5029","authenticated-orcid":false,"suffix":"III","given":"Clifton O.","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5413-9345","authenticated-orcid":false,"given":"Marcy B.","family":"Bolster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-7818","authenticated-orcid":false,"given":"Daniel J.","family":"Clauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7963-4206","authenticated-orcid":false,"given":"Wendy","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2105-3393","authenticated-orcid":false,"given":"Yvonne C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"2023061203300617000_50.5.684.1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/rheumatology\/key054","article-title":"Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden","volume":"58","author":"Einarsson","year":"2019","journal-title":"Rheumatology"},{"key":"2023061203300617000_50.5.684.2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151132"},{"key":"2023061203300617000_50.5.684.3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1741-7015-11-17","article-title":"Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?","volume":"11","author":"Rom\u00e3o","year":"2013","journal-title":"BMC Med"},{"key":"2023061203300617000_50.5.684.4","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1093\/rheumatology\/keaa529","article-title":"Predicting treatment response to IL6R blockers in rheumatoid arthritis","volume":"59","author":"Nouri","year":"2020","journal-title":"Rheumatology"},{"key":"2023061203300617000_50.5.684.5","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.mayocp.2017.05.009","article-title":"Prediction of response to targeted treatment in rheumatoid arthritis","volume":"92","author":"Wijbrandts","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2023061203300617000_50.5.684.6","doi-asserted-by":"publisher","DOI":"10.3310\/hta22440"},{"key":"2023061203300617000_50.5.684.7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11914-018-0473-5","article-title":"Mechanisms for joint pain in rheumatoid arthritis (RA): from cytokines to central sensitization","volume":"16","author":"Zhang","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"2023061203300617000_50.5.684.8","doi-asserted-by":"publisher","DOI":"10.1186\/ar3353"},{"key":"2023061203300617000_50.5.684.9","first-page":"94","article-title":"Pain mechanisms in rheumatoid arthritis","volume":"35","author":"McWilliams","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2023061203300617000_50.5.684.10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/14397595.2017.1416940","article-title":"Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review","volume":"28","author":"Ishida","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2023061203300617000_50.5.684.11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/acr.23266","article-title":"Association between pain sensitization and disease activity in patients with rheumatoid arthritis: a cross-sectional study","volume":"70","author":"Lee","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2023061203300617000_50.5.684.12","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/art.41440","article-title":"Association of dysregulated central pain processing and response to disease\u2013modifying antirheumatic drug therapy in rheumatoid arthritis","volume":"72","author":"Heisler","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2023061203300617000_50.5.684.13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20140"},{"key":"2023061203300617000_50.5.684.14","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/acr.23994","article-title":"Association of pain centralization and patient-reported pain in active rheumatoid arthritis","volume":"72","author":"Heisler","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2023061203300617000_50.5.684.15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/acr.23617","article-title":"Responsiveness of Patient-Reported Outcomes Measurement Information System measures in rheumatoid arthritis patients starting or switching a disease-modifying antirheumatic drug","volume":"71","author":"Wohlfahrt","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2023061203300617000_50.5.684.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2023061203300617000_50.5.684.17","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084459"},{"key":"2023061203300617000_50.5.684.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.001"},{"key":"2023061203300617000_50.5.684.19","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00296-017-3792-4","article-title":"The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis","volume":"37","author":"Salaffi","year":"2017","journal-title":"Rheumatol Int"},{"key":"2023061203300617000_50.5.684.20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key075.533"},{"key":"2023061203300617000_50.5.684.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.06.005"},{"key":"2023061203300617000_50.5.684.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev254"},{"key":"2023061203300617000_50.5.684.23","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0525-5"},{"key":"2023061203300617000_50.5.684.24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130493"},{"key":"2023061203300617000_50.5.684.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.56.4.268"},{"key":"2023061203300617000_50.5.684.26","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21931"},{"key":"2023061203300617000_50.5.684.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141519"},{"key":"2023061203300617000_50.5.684.28","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.2147\/JPR.S147199","article-title":"Characterizing classes of fibromyalgia within the continuum of central sensitization syndrome","volume":"11","author":"Davis","year":"2018","journal-title":"J Pain Res"},{"key":"2023061203300617000_50.5.684.29","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22300"},{"key":"2023061203300617000_50.5.684.30","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/acr.23216","article-title":"Fibromyalgia and the prediction of two-year changes in functional status in rheumatoid arthritis patients","volume":"69","author":"Kim","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2023061203300617000_50.5.684.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2018.01.010"},{"key":"2023061203300617000_50.5.684.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2012.07.005"},{"key":"2023061203300617000_50.5.684.33","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220046"},{"key":"2023061203300617000_50.5.684.34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/AJP.0000000000000316","article-title":"The Fibromyalgia Survey Score correlates with preoperative pain phenotypes but does not predict pain outcomes after shoulder arthroscopy","volume":"32","author":"Cheng","year":"2016","journal-title":"Clin J Pain"},{"key":"2023061203300617000_50.5.684.35","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000000637"},{"key":"2023061203300617000_50.5.684.36","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3182a8eb1f"},{"key":"2023061203300617000_50.5.684.37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg075"},{"key":"2023061203300617000_50.5.684.38","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket301"},{"key":"2023061203300617000_50.5.684.39","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.semarthrit.2015.07.001","article-title":"Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice","volume":"45","author":"Narv\u00e1ez","year":"2016","journal-title":"Semin Arthritis Rheum"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.220507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T10:31:28Z","timestamp":1686565888000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.220507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,1]]},"published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.3899\/jrheum.220507"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.220507","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]}}}